Sanofi has introduced new 24-count and 32-count tablet packages for its tuberculosis treatment medicine Priftin (rifapentine).
The new packs have been customised to manage dosage regimens for the medicine, which is used as an antimicrobial for treatment of latent and active tuberculosis (TB).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The packaging also feature individually perforated tablet blisters and individual tablet printing on the backing foil, Sanofi said, and can offer benefits of an extended shelf-life for up to three years.
Sanofi global chief medical officer Paul Chew said: "For more than 50 years, Sanofi has provided treatment and programmes that equip patients and their healthcare providers to fight TB."
Priftin is used along with one or more antituberculosis drugs for treating active pulmonary tuberculosis in adults and children aged 12 years and older.
The antimycobacterial drug is also used to cure latent tuberculosis infection (LTBI) in patients aged two years or older having high risk for tuberculosis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to World Health Organization (WHO) estimates, up to 13 million US residents suffer from LTBI. Between 5% and 10% of the LTBI-affected patients progress to turn into an active TB patient if not treated.
Image: The new packages have an extended shelf-life of up to three years. Photo: courtesy of Sanofi.
